BidaskClub Downgrades Ironwood Pharmaceuticals (IRWD) to Hold

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Thursday.

A number of other brokerages have also recently issued reports on IRWD. Mizuho reiterated a “buy” rating and set a $20.00 target price (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a research report on Friday, August 25th. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday. Cowen set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Credit Suisse Group started coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $17.88.

Shares of Ironwood Pharmaceuticals (IRWD) traded down $0.03 during trading on Thursday, hitting $15.09. 1,271,082 shares of the company were exchanged, compared to its average volume of 1,308,441. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. Ironwood Pharmaceuticals has a 1-year low of $13.43 and a 1-year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. The business had revenue of $86.80 million during the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The firm’s revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) EPS. equities research analysts forecast that Ironwood Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 5.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares during the last quarter. Aperio Group LLC boosted its stake in Ironwood Pharmaceuticals by 11.9% during the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 1,410 shares during the last quarter. Amalgamated Bank boosted its stake in Ironwood Pharmaceuticals by 9.0% during the 2nd quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 1,421 shares during the last quarter. Virtu KCG Holdings LLC boosted its stake in Ironwood Pharmaceuticals by 10.3% during the 2nd quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 1,470 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Ironwood Pharmaceuticals by 5.0% during the 2nd quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 2,265 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Ironwood Pharmaceuticals (IRWD) to Hold” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/08/bidaskclub-downgrades-ironwood-pharmaceuticals-irwd-to-hold.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply